Pfizer publicly dropped race-based selection criteria from an internship program that discriminated against white and Asian applicants, settling a lawsuit with Do No Harm, an organization committed to safeguarding the medical industry from leftwing ideology.
The pharmaceutical giant settled with Do No Harm after the organization launched a lawsuit challenging Pfizer’s Breakthrough Fellowship program, which originally excluded white and Asian would-be applicants on the basis of their race.
Do No Harm Chairman Dr. Stanley Goldfarb touted the victory, noting that the settlement amounts to an admission from the company that they were previously engaged in unlawful racial discrimination.
“While Pfizer would like to quietly sweep their unlawful discrimination under the rug, their settlement acknowledges what we said all along: racially discriminatory programs are unlawful and will not go…
